Dr. Christopher J. Logothetis has a longstanding interest in genitourinary cancers—germ cell tumors, bladder, renal, and most recently in his career, prostate cancer. His research experience preceded the development of effective chemotherapy and extends to the current era of molecular targeted therapies and classification of cancer. He was among the first to test chemotherapy agents at a time of general skepticism that chemothera
py would be useful in advanced prostate cancer.
Dr. Logothetis is Director of the Genitourinary Cancer Center and Director of the Prostate Cancer Research Program, which have integrated more than 60 faculty from 7 departments in clinical and basic research studies in prostate cancer. He is the Principal Investigator of the MD Anderson Cancer Center Prostate SPORE (Specialized Programs of Research Excellence), a 5-year, multidisciplinary, collaborative grant funded by the National Cancer Institute. Dr. Logothetis has keen insight into the potential for change and the importance of collaborations among colleagues in academic medicine, community physicians, and patient support and advocacy communities.
On the national level, Dr. Logothetis has been appointed to the Board of Scientific Advisors of the NCI and is a member of the External Advisory Committee for the NCI-sponsored project to characterize the human cancer genome.
Dr. Logothetis is a fervent proponent of improving the translational research environment to align clinical care with research goals. The David H. Koch Center for Applied Research of Genitourinary Cancers, of which he is Director, reflects the success achieved by thoughtful physician and scientist recruitments, productive intramural and extramural collaborations; education and training of young investigators, and development of critical common resources.
Dr. Logothetis received his MD degree from the University of Athens (Greece) and completed internship and residency training at Cook County Hospital in Chicago. On completion of his fellowship at M. D. Anderson Cancer Center, he joined the faculty.
Dr. Kumar is a professor and medical oncologist in Tata Memorial Hospital and has more than two decades of experience. He is the present President and convener of Indian Cooperative Oncology Network (ICON).He has so far published over a hundred research and review articles/papers in journals of national and international repute. He has so far undertaken over 80 projects as Principal Investigator and Co-Investigator.
Tata Memorial Centre Advanced Centre for Treatment, Research and Education in Cancer, Mumbai
|Principal Investigator||Advanced Centre for Treatment, Researchand Education in Cancer, Navi Mumbai, India||Present|
|Post Doctoral Fellowship||Max Planck Institute for Immunology,Freiburg, Germany||1984-1986|
Dr. Gopal Chandra Kundu is an renowned Indian cell and cancer biologist and the current Director In-charge at National Centre for Cell Science. He is
known for his contributions towards the understanding the mechanism of cancer progression in breast, melanoma and other cancers and development of novel therapeutic targets and target-based therapy in cancers.
Tumor Biology, Regulation of Gene Expression, Chemical Biology,Angiogenesis and Nanomedicine
Dr. Mani’s original finding demonstrating the cancer cells acquire stem cell properties by activating latent embryonic epithelial-mesenchymal transition (EMT) program provided the foundation and explanation for the presence of plasticity within the tumor as well as the development of resistance to various treatments. Based on this key finding, various biotech companies are targeting EMT signaling pathways to inhibit tumor plasticity and the associated metastasis and therapy resistance.
Dr. Subbiah has a unique training background as he is one of the few physicians in the nation/world to have training in oncology in both adults and children. He is board certified in both Internal Medicine and Pediatrics and has completed fellowships in both adult and pediatric oncology at the MD Anderson Cancer Center. Dr. Subbiah has been working closely with colleagues in Cancer Medicine and Pediatrics to develop novel treatment methods including molecularly targeted therapies, radiopharmaceutical studies and immunotherapeutic strategies
to improve the outcomes of AYA with cancer.
Dr Rama’s research interests can be broadly divided into 3 major categories –
1) understanding the context-dependent role of pleiotropic signaling cascades in the progression of variant/neuroendocrine prostate cancers;
2) investigating the molecular links between hypertension and cancer, and
3) identifying determinants of metastatic competence in breast and prostate
Dr. Sharmila Bapat is a group leader of the Ovarian Cancer Program at the National Centre for Cell Science, Pune, India and has to her credit the first report on the isolation and identification of cancer stem cells in ovarian cancer. More recently she has been integrating basic biology with computational approaches to elucidate resolution of tumor heterogeneity and systems based network analyses of biological functions of tumor cells.Abstract
Dr. Rangarajan’s current research interest includes: Understanding the mechanisms of self-renewal in normal and cancer stem cells; Identification of a novel AMPK-PEA15 axis in the anoikis-resistant growth of mammary cells; A monoclonal antibody against human Notch1 ligand-binding domain depletes subpopulation of putative breast cancer stem-like cells.